ArriVent BioPharma released initial encouraging Phase 1 data for the ARR-217 ADC showing a 44.8% ORR at 6mg/kg in colorectal cancer patients, generally well-tolerated, and sent the stock higher post-debut.
ArriVent BioPharma released initial encouraging Phase 1 data for the ARR-217 ADC showing a 44.8% ORR at 6mg/kg in colorectal cancer patients, generally well-tolerated, and sent the stock higher post-debut.